View all CSAC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources

PER Pulse™ Recap
for Cancer Summaries and Commentaries™: Update From Orlando: Advances in Non-Hodgkin Lymphoma focuses on trials likely to be of interest to practicing hematologists, immediately or in the near future. Each Recap provides a brief overview of trial data, along with a summary of expert perspective.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Genentech.


Cancer Summaries and Commentaries™: Update from Orlando: Advances in Non-Hodgkin Lymphoma


Release Date: January 29, 2016
Expiration Date: January 29, 2017
Media: Internet - based

Activity Overview

This activity is designed to update physicians on the data that have been recently presented in Orlando so that they can assess and prepare to apply these findings to their clinical practice to improve patient care.

CME Activity Table of Contents

  • Towards Improving Outcome for Patients With Non-GCB-DLBCL: PYRAMID and REMoDL-B Trials
  • Phase 2 Trial of Ibrutinib Plus Rituximab in Patients With Previously Untreated Follicular Lymphoma
  • Analysis of Minimal Residual Disease in the Phase 3 GADOLIN trial of Bendamustine With or Without Obinutuzumab in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
  • Phase 2 Trial of Risk-Adapted Therapy with DA-EPOCH-R in Adult Patients With Burkitt Lymphoma
  • Investigating BCL-2 Inhibition With Venetoclax in Patients with Non-Hodgkin Lymphoma
  • Exploration of CTL019 Chimeric Antigen Receptor-Modified T-Cell Therapy in Patients With Non-Hodgkin Lymphomas

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.


Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Optimize management and treatment strategies for patients with NHL, based on efficacy and safety, as well as patient characteristics, clinical condition, and prognosis
  • Evaluate clinical trial data on new agents and approaches in development for the treatment and management of patients with NHL


Faculty, Staff, and Planners' Disclosures

Faculty

John P. Leonard, MD
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York, NY
Disclosure: Consultant: Celgene, ADC Therapeutics, Biotest, Medimmune, Nospira, Bayer, Juno, Teva, OncoTracker, Gilead Sciences.

Laurie Sehn, MD
Clinical Assistant Professor
Medical Oncology
University of British Columbia
Vancouver, Canada
Disclosure: Consultant: Amgen, Genentech, Gilead, AbbVie, Seattle Genetics, Lundbeck, Celgene.

 

The following individuals have no relevant financial relationships with commercial interests:

The staff of PER®, LLC.


Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.


Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.


Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By